1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med. 1999;341:709-717.

2. Schepkens H, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone. Am J Med. 2001;110:438-441.

3. Berry C, McMurray J. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone. Am J Med. 2001;111:587. Letter.

4. Blaustein DA et al. Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and antiotensin-converting enzyme inhibition or antiotensin receptor blockade. Am J Cardiol. 2002;90:662-663.

5. Wrenger E et al. Interaction of spironolactone with ACE inhibitors or antiogensin receptor blockers: analysis of 44 cases. Br Med J. 2003;327:147-149.